Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET

NCT05750290 is registered in ClinicalTrials.gov with National Cancer Center, Korea as lead sponsor.

NCT NCT05750290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05750290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET
Lead sponsor
National Cancer Center, Korea
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2022
Completion date
December 31, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer